Coma, dry skin and mucous membranes, enlarged pupils of the eyes, extremely high body temperature, flushing, involuntary eyeball movement, lower than normal muscle tone, pinpoint pupils, rapid heartbeat, restlessness, sluggishness, suppressed breathing
A meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity. This medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations. When diphenoxylate is used alone, it is classified as a Schedule II.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Diphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate. |
| Hydrocodone | Diphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate. |
| Magnesium sulfate | The therapeutic efficacy of Diphenoxylate can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Diphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Diphenoxylate may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate. |
| Orphenadrine | Diphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Diphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate. |
| Pramipexole | Diphenoxylate may increase the sedative activities of Pramipexole. |
| Ropinirole | Diphenoxylate may increase the sedative activities of Ropinirole. |
| Rotigotine | Diphenoxylate may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Diphenoxylate. |
| Sodium oxybate | Diphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Diphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate. |
| Thalidomide | Diphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Diphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Alvimopan | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Alvimopan. |
| Desmopressin | The risk or severity of hyponatremia can be increased when Diphenoxylate is combined with Desmopressin. |
| Morphine | The risk or severity of adverse effects can be increased when Morphine is combined with Diphenoxylate. |
| Codeine | The risk or severity of adverse effects can be increased when Codeine is combined with Diphenoxylate. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Hydromorphone is combined with Diphenoxylate. |
| Meperidine | The risk or severity of adverse effects can be increased when Meperidine is combined with Diphenoxylate. |
| Oxycodone | The risk or severity of adverse effects can be increased when Oxycodone is combined with Diphenoxylate. |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Diphenoxylate. |
| Naltrexone | The therapeutic efficacy of Diphenoxylate can be decreased when used in combination with Naltrexone. |
| Sufentanil | The risk or severity of adverse effects can be increased when Sufentanil is combined with Diphenoxylate. |
| Alfentanil | The risk or severity of adverse effects can be increased when Alfentanil is combined with Diphenoxylate. |
| Fentanyl | The risk or severity of adverse effects can be increased when Fentanyl is combined with Diphenoxylate. |
| Levorphanol | The risk or severity of adverse effects can be increased when Levorphanol is combined with Diphenoxylate. |
| Remifentanil | The risk or severity of adverse effects can be increased when Remifentanil is combined with Diphenoxylate. |
| Oxymorphone | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Oxymorphone. |
| Dezocine | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dezocine. |
| Methadyl acetate | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methadyl acetate. |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dihydroetorphine. |
| Diamorphine | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Diamorphine. |
| Bezitramide | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Bezitramide. |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethylmorphine. |
| Etorphine | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Etorphine. |
| Dextromoramide | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dextromoramide. |
| Desomorphine | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Desomorphine. |
| Carfentanil | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Carfentanil. |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dihydrocodeine. |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Alphacetylmethadol. |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dihydromorphine. |
| Ketobemidone | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ketobemidone. |
| DPDPE | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with DPDPE. |
| Lofentanil | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lofentanil. |
| Opium | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Opium. |
| Normethadone | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Normethadone. |
| Piritramide | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Piritramide. |
| Alphaprodine | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Alphaprodine. |
| Nicomorphine | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Nicomorphine. |
| Meptazinol | The therapeutic efficacy of Diphenoxylate can be decreased when used in combination with Meptazinol. |
| Phenoperidine | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Phenoperidine. |
| Phenazocine | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Phenazocine. |
| Tilidine | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tilidine. |
| Carfentanil, C-11 | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Carfentanil, C-11. |
| Naloxegol | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Naloxegol. |
| Benzhydrocodone | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Benzhydrocodone. |
| Pegvisomant | The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Diphenoxylate. |
| Succinylcholine | The risk or severity of bradycardia can be increased when Succinylcholine is combined with Diphenoxylate. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Diphenoxylate. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Diphenoxylate. |
| Mirtazapine | Diphenoxylate may increase the serotonergic activities of Mirtazapine. |
| Fluvoxamine | The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Fluvoxamine. |
| Citalopram | The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Citalopram. |
| Duloxetine | The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Duloxetine. |
| Paroxetine | The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Paroxetine. |
| Sertraline | The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Sertraline. |
| Sibutramine | The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Sibutramine. |
| Nefazodone | The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Nefazodone. |
| Zimelidine | The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Zimelidine. |
| Dapoxetine | The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Dapoxetine. |
| Milnacipran | The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with Diphenoxylate. |
| Seproxetine | The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Seproxetine. |
| Levomilnacipran | The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Levomilnacipran. |
| Indalpine | The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Indalpine. |
| Ritanserin | The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Ritanserin. |
| Alaproclate | The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Alaproclate. |
| Ethanol | Diphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Diphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate. |
| Amphetamine | Amphetamine may increase the analgesic activities of Diphenoxylate. |
| Phentermine | Phentermine may increase the analgesic activities of Diphenoxylate. |
| Pseudoephedrine | Pseudoephedrine may increase the analgesic activities of Diphenoxylate. |
| Benzphetamine | Benzphetamine may increase the analgesic activities of Diphenoxylate. |
| Diethylpropion | Diethylpropion may increase the analgesic activities of Diphenoxylate. |
| Lisdexamfetamine | The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Lisdexamfetamine. |
| Mephentermine | Mephentermine may increase the analgesic activities of Diphenoxylate. |
| MMDA | MMDA may increase the analgesic activities of Diphenoxylate. |
| Midomafetamine | Midomafetamine may increase the analgesic activities of Diphenoxylate. |
| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Diphenoxylate. |